Catherine A. Koivisto, RPh

Using new treatment advances, traditional medications, genetic profiles, immunotherapies, and individualized plans enables providers to improve outcomes for patients with TPBC.

Topical, targeted drug delivery increases drug concentrations at the desired site while also reducing toxicity and unwanted adverse effects.

Hokkaido scallop oil plasmalogen and Apoaequorin have both been posited to improve brain health.

Measuring end points such as molecular response, cytokines, and histomorphometry may show a greater range of benefits.

The use of CGMs in pregnancy provides clinicians with essential data in real-time, rather than a snapshot given by traditional finger stick testing.